Portfolio

Innovative Nanobiopharmaceutics

The innovative nanobiopharmaceutics is a socially significant cluster of RUSNANO, which includes 10 enterprises that actually created from scratch their in-house production of both innovative medicines, and generics in one of the fastest growing industries in Russia—pharmaceutical. The main segment of the market of nanomedicine (taking up around 90%) is the application of nanomaterials to create highly effective medicines and vaccines with a good safety profile. The actual production level in this cluster amounted to 13 billion rubles in 2016.

 
  • Selecta Biosciences, Inc. & Selecta RUS
    Selecta Biosciences, Inc. & Selecta RUS

    Development and commercialization of an entirely new class of targeted vaccines that induce antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications.

    Operating Factories
    from november 2012

    Moscow

  • Pharmsynthez, OJSC
    Pharmsynthez, OJSC

    Pharmsynthez will bring a number of unique and much-needed drugs to Russian and global markets. During this investment phase, clinical trials of the drugs that Pharmsynthez developed will be completed, their large-scale manufacturing will begin, and the drugs will be brought to foreign markets.

    Operating Factories

  • BIND Therapeutics & BIND RUS
    BIND Therapeutics & BIND RUS

    Exit
    Development and commercialization of a new class of highly selective targeted therapeutics based on BIND Biosciences’s Accurins™ nanoplatform.

    Operating Factories

  • Nearmedic Pharma
    Nearmedic Pharma

    Exit
    Full-cycle production of innovative nanomedicines via versatile GMP pharmaceutical manufacturer.

  • NANOLEK LLC
    NANOLEK LLC

    Production of import-substituting innovative pharmaceuticals.

    Operating Factories

  • Panacela Labs, Inc.
    Panacela Labs, Inc.

    Development of the anti-cancer drugs based on the molecular modulators of cellular stress, as well as the treatments against infectious diseases. Currently, company portfolio consists of 5 drug families.

  • NTpharma
    NTpharma

    GMP production of nanovaccines and biopharmaceuticals containing carbohydrate binders.